West Nile Infection
A special issue of Tropical Medicine and Infectious Disease (ISSN 2414-6366). This special issue belongs to the section "Vector-Borne Diseases".
Deadline for manuscript submissions: closed (1 November 2022) | Viewed by 28228
Special Issue Editor
Special Issue Information
Dear Colleagues,
West Nile virus (WNV) represents the main cause of arboviral central nervous system (CNS) infection in the Western world. During the last decade, WNV outbreaks have progressively become more frequent worldwide. Specifically, the 2018 West Nile Virus (WNV) season was characterized by extraordinary high rates of WNV infections worldwide, especially in Europe. Whereas the majority of WNV infections are asymptomatic, a minority of patients can develop clinical manifestations, which range from mild febrile illness to devasting central nervous system involvement. WNV neuroinvasive forms can be extremely acute and severe. Overall mortality has been assessed around 10%. Prognosis strongly relates to the host’s pre-existing conditions (age, comorbidities, and immunological status). The diagnosis of WNV is principally based on clinical suspicion and laboratory confirmation through serologic tests and by viral nucleic acid testing in CSF, tissue, blood, or other body fluid. However, both techniques have significant pitfalls. Regarding serology, the usual serological enzyme-linked immunosorbent assay (ELISA) lacks specificity, as IgM can cross-react with other flaviviruses; nevertheless, IgM can persist for months after the primary infection, and some patients (e.g., those who are immunocompromised) cannot mount a specific antibody response. Furthermore, viremia is extremely fleeting, despite prolonged clinical manifestation. Specific antiviral treatment against WNV is lacking. A number of antiviral compounds (including interferon and high dose ribavirin) have been proposed as potentially active in vitro; however, no randomized control trials has been designed. Real-life analysis and case reports have also suggested that corticosteroids and passive immunization through intravenous immunoglobulin could be interesting treatment options. Given this premise, prevention of WNV infection appears crucial. However, no human vaccine has been licensed for human use so far. In our opinion, there are several interesting topics to explore, in order to expand the knowledge regarding this fascinating disease. With this Special Issue, we wish to invite our colleagues to submit original manuscripts, research papers, and meta-analyses, to build a systematic collection of the available knowledge about WNV.
The themes we propose for the research include, but are not limited to, the following:
- Virology of WNV;
- Vector control;
- Clinical presentation in general population and “special categories”;
- WNV in immunocompromised hosts;
- Immunological aspects;
- Diagnostic methods;
- Organ and blood safety;
- Treatment options:
a. Antivirals;
b. Immunomodulating agents;
c. Immunoglobulins.
Dr. Maddalena Peghin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tropical Medicine and Infectious Disease is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- arthropods
- vector-borne
- West Nile
- immunoglobulin
- mosquito
- transplant
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.